{
  "id": "alterity-therapeutics-reports-strong-cash-position-and-phase-3-planning-progress",
  "title": "Alterity Therapeutics reports strong cash position and Phase 3 planning progress",
  "summary": "Alterity Therapeutics Ltd. released its Appendix 4C quarterly cash flow report and corporate update for Q2 FY 26 (quarter ending 31 December 2025), showing continued advancement of its neurodegenerative disease pipeline alongside solid financial footing, the company said. During the quarter, Alterity said that Phase 2 clinical data for its lead candidate, ATH434, in multiple [â€¦] The post Alterity Therapeutics reports strong cash position and Phase 3 planning progress appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/alterity-therapeutics-reports-strong-cash-position-and-phase-3-planning-progress/",
  "source": "Longevity.Technology",
  "author": null,
  "category": "news",
  "publishedAt": "2026-01-31T08:31:06.000Z",
  "fetchedAt": "2026-02-04T10:49:05.817Z",
  "relevanceScore": 0.2,
  "matchedKeywords": [
    "longevity"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.889Z"
}